CD79a Antibody

The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD79a antibody to be titered up or down for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B-cell Ag receptor. CD79a first appears at pre B-cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. It is found in the majority of acute leukemias of B-cell precursors, lines and lymphomas, and in some myelomas. It is not present in myeloid or Tcell lines. CD79a antibody is generally used to complement CD20 mAb, especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This CD79a antibody will stain many of the same lymphomas as CD20 mAb, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is CD20 mAb. CD79a antibody also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.

Purified

Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*

973

A soluble form of the extracellular IgSF domain from the human protein was used as the immunogen for the CD79a antibody.

This CD79a antibody is available for research use only.

Cell surface, cytoplasmic

Protein G affinity chromatography